Selway Asset Management lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 8,323 shares of the medical instruments supplier’s stock after purchasing an additional 100 shares during the period. Becton Dickinson and comprises approximately 1.4% of Selway Asset Management’s portfolio, making the stock its 26th largest holding. Selway Asset Management’s holdings in Becton Dickinson and were worth $2,079,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in BDX. Standard Life Aberdeen plc grew its position in shares of Becton Dickinson and by 2.5% during the third quarter. Standard Life Aberdeen plc now owns 129,845 shares of the medical instruments supplier’s stock worth $33,890,000 after buying an additional 3,134 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Becton Dickinson and during the third quarter worth about $453,000. AQR Capital Management LLC grew its position in shares of Becton Dickinson and by 36.9% during the third quarter. AQR Capital Management LLC now owns 143,712 shares of the medical instruments supplier’s stock worth $37,509,000 after buying an additional 38,709 shares in the last quarter. Kentucky Retirement Systems acquired a new position in shares of Becton Dickinson and during the third quarter worth about $1,771,000. Finally, Teachers Advisors LLC grew its position in shares of Becton Dickinson and by 0.7% during the third quarter. Teachers Advisors LLC now owns 488,441 shares of the medical instruments supplier’s stock worth $127,483,000 after buying an additional 3,366 shares in the last quarter. 84.87% of the stock is owned by institutional investors and hedge funds.

BDX stock opened at $227.89 on Friday. The company has a market cap of $61.32 billion, a P/E ratio of 20.70, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $265.87. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.48 earnings per share. As a group, sell-side analysts anticipate that Becton Dickinson and Co will post 12.08 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date was Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

In other Becton Dickinson and news, EVP Ribo Alberto Mas sold 2,104 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $255.00, for a total value of $536,520.00. Following the completion of the sale, the executive vice president now owns 19,074 shares in the company, valued at $4,863,870. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Vincent A. Forlenza sold 3,123 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the sale, the chief executive officer now owns 215,372 shares of the company’s stock, valued at approximately $54,926,321.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is owned by company insiders.

BDX has been the subject of a number of analyst reports. Barclays boosted their price objective on Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Raymond James decreased their target price on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research note on Tuesday, March 19th. Zacks Investment Research cut Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Citigroup decreased their target price on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. Finally, Morgan Stanley decreased their target price on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus target price of $256.25.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/selway-asset-management-has-2-08-million-stake-in-becton-dickinson-and-co-bdx/2979216.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.